[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rubella\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rubella":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,151,172,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100649909","phase-3-a-study-on-the-immune-response-and-safety-of-an-investigational-combined-measles-mumps-rubella-and-varicella-vaccine-when-given-to-healthy-children-4-to-6-years-of-age-100649909",false,"NCT07742644","A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age","A Phase 3a, Observer-blind, Randomized, Controlled Study to Demonstrate Lot-to-lot Consistency and Evaluate the Immunogenicity and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine Compared With ProQuad, Administered as a Second Dose in Healthy Children 4-6 Years of Age","MMRVNS 20-002","Inclusion Criteria (INC):\n\n* INC#1 Participant's parent(s)\u002FLAR(s), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).\n* INC#2 Written or witnessed\u002Fthumb printed or digital informed consent obtained from the participant's parent(s)\u002FLAR(s) prior to performance of any study specific procedure.\n* INC#3 Informed assent obtained from the participants in line with local rules and regulations.\n* INC#4 Healthy participants as established by medical history and clinical examination at screening.\n* INC#5 A male or female participant between and including 4 and 6 years of age (i.e., from fourth birthday until the day before the seventh birthday) at the time of the study interventions administration, and in accordance with local regulations.\n* INC#6 Participant who previously received a first dose of varicella-containing vaccine in the second year of life (i.e., from first birthday at 12 months of age until the day before the second birthday at 24 months of age).\n* INC#7 Participant who previously received a first dose of measles, mumps, rubella containing vaccine in the second year of life (i.e., from first birthday at 12 months of age until the day before the second birthday at 24 months of age).\n* INC#8 Participant who previously received 3 or 4 doses of any combined DTP (DTaP\u002FDTwP) vaccine (diphtheria and tetanus toxoids and pertussis antigens whether or not combined with hepatitis B, inactivated poliovirus or Haemophilus influenzae type b antigens) according to the local recommendations.\n\nExclusion Criteria (EXC):\n\n* EXC#1 History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions, including hypersensitivity to neomycin or gelatin.\n* EXC#2 Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* EXC#3 Hypersensitivity to latex.\n* EXC#4 Unstable chronic conditions as determined by medical history and physical examination.\n* EXC#5 Major congenital defects, as assessed by the investigator.\n* EXC#6 History of measles, mumps, rubella or varicella\u002Fzoster disease as evaluated by the investigator.\n* EXC#7 History of diphtheria, tetanus, pertussis, and\u002For poliomyelitis disease.\n* EXC#8 Recurrent history or uncontrolled neurological disorders or any neuroinflammatory (including, but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, or seizures (including all subtypes, such as: absence seizures, generalized tonic-clonic seizures, partial complex seizures, partial simple seizures).\n* EXC#9 Active untreated tuberculosis.\n* EXC#10 Condition that, in the judgment of the investigator, would make intramuscular injection unsafe.\n* EXC#11 Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.\n* EXC#12 Use of any investigational or non-registered product (drug, vaccine, or invasive medical device in the country of enrollment) other than the study interventions during the period beginning 30 days before the dose of study interventions (Day -29 to Day 1), or their planned use during the study period.\n* EXC#13 Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.\n* EXC#14 Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and\u002For planned use of long-acting immune modifying treatments at any time up to the end of the study.\n\n  * Up to 90 days prior to the study interventions administration.\n\n    * For corticosteroids, this will mean prednisone equivalent ≥0.5 mg\u002Fkg\u002Fday with maximum of 20 mg\u002Fday for pediatric participants. Inhaled, intra-articular\u002Fintra-bursal and topical steroids are allowed.\n  * Up to 180 days prior to study interventions administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study interventions, e.g., nirsevimab), antitumoral medication.\n* EXC#15 Previous vaccination with a second dose of varicella-containing vaccine or measles, mumps, rubella containing vaccine.\n* EXC#16 Vaccination against diphtheria, tetanus, pertussis, and\u002For poliomyelitis given after the second year of life (i.e., after the second birthday at 24 months of age).\n* EXC#17 Occurrence of any of the following events after a previous administration of DTP vaccine:\n\n  * Encephalopathy of unknown etiology occurring during the period starting within 7 days of vaccination of a previous administration of DTP vaccine.\n  * A temperature (≥40.6°C \\[≥105°F\\]) during the period starting 48 hours after vaccination not due to another identifiable cause.\n* EXC#18 Use of salicylates (aspirin) or salicylate-containing products or its planned use, during the period of 6 weeks following study interventions administration.\n* EXC#19 Planned administration\u002Fadministration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 43 days after the dose of study interventions administration\\* (Visit 2), with the exception of\n\nInfluenza vaccines:\n\n* Inactivated influenza vaccine must not be administered in the period starting 28 days before the dose and ending 28 days after the dose of study intervention administration. If administered outside this prohibited period, it should be administered at a different location than the study intervention.\n* Live attenuated influenza vaccine must not be administered during the period starting 30 days before the dose and ending 43 days after the dose of study intervention administration (Visit 2).\n\n  * If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and\u002For organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and sponsor is notified.\n\n    * EXC#20 Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug\u002Fvaccine\u002Finvasive medical device).\n    * EXC#21 Any study personnel's immediate dependents, family, or household members.\n    * EXC#22 Child in care.\n    * EXC#23 Participants with the following high-risk individuals in their household:\n\n      * Immunocompromised individuals.\n      * Pregnant women without documented history of varicella.\n      * Newborn infants of mothers without documented history of varicella.\n      * Newborn infants born \\\u003C28 weeks of gestation.",true,"ALL","4 Years","6 Years",{"count":22,"type":23},1860,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response. It will also compare the overall immune response to the MMRVNS vaccine with that of the Merck licensed measles, mumps, rubella, and varicella (MMRV) vaccine.\n\nThe vaccines will be given as a second dose to children aged 4 to 6 years who have previously received a first dose of any combination of measles, mumps, rubella, and varicella-containing vaccine(s).\n\nThe study will also assess the immune response and safety of the MMRVNS and MMRV vaccines when given at the same time as a diphtheria, tetanus, acellular pertussis, and inactivated poliovirus (DTaP-IPV) vaccine. The DTaP-IPV vaccine used is licensed as Kinrix in the United States.",[29,30,31,32,33],"Measles","Mumps","Rubella","Varicella (Chickenpox)","Measles-Mumps-Rubella+Chickenpox Vaccine",[29,30,31,32,35,36,37,38],"Combined vaccine","Immunogenicity","Vaccine safety","Children aged 4 to 6 years","NOT_YET_RECRUITING","2026-07-29",{"date":42,"type":43},"2026-08-03","ACTUAL",{"date":45,"type":23},"2026-08-11",{"date":47,"type":23},"2028-11-21",{"name":49,"class":50},"GlaxoSmithKline","INDUSTRY",62,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":121,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":150},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":62,"type":23},10000,"OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,29,30,31,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":142,"type":43},"2026-01-22",{"date":144,"type":43},"2025-12-18",{"date":146,"type":23},"2027-09-30",{"name":148,"class":149},"Institut Pasteur du Cambodge","OTHER",1,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100618994","the-five-year-antibody-persistence-after-immunization-with-ipv-mmr-and-hepa-l-vaccines-100618994","NCT07338851","the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","Evaluation on the Persistence of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell), Combined Live Attenuated Measles, Mumps and Rubella Vaccine and Freeze-dried Live Attenuated Hepatitis A Vaccine in Chinese Children: Up to 5 Years of Follow-up","Inclusion Criteria:\n\n* Participants in the NCT04638985 or NCT04636827, and who have completed the vaccination of designated batch numbers of sIPV, MMR or HepA-L vaccines;\n* The time window from the day of enrollment to the date when the participants received the fourth dose of sIPV vaccine, the second dose of MMR vaccine, or the first dose of HepA-L vaccine was 60 to 66 months.\n* The informed consent form shall be signed by the participant or his\u002Fher legal guardian and dated.\n\nExclusion Criteria:\n\n* None.",{"count":159,"type":23},600,"This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.",[162,29,31,30,94],"Polio","2026-01-04",{"date":140,"type":43},{"date":166,"type":23},"2026-01-30",{"date":168,"type":23},"2027-12-31",{"name":170,"class":50},"China National Biotec Group Company Limited",6,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100601619","prospective-clinical-registry-for-evaluation-of-exanthematous-infections-and-coinfections-100601619","NCT07112846","Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","CRIUS","Inclusion Criteria:\n\nIndividuals from newborns (zero years old) to 18 years of age, of both sexes.\n\nSuspected individuals with the following criteria:\n\nMeasles: Presenting fever and rash associated with cough and\u002For runny nose and\u002For conjunctivitis, regardless of age or vaccination status;\n\nRubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;\n\nDengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and\u002For lymph node enlargement;\n\nIndividuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases.\"\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":181,"type":23},830,"Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.",[184,185,67,29,31],"Exanthema","Dengue Fever",[187,188,67,189,190,191],"exanthema","dengue fever","measles","rubella","epidemiology","2025-08-01",{"date":194,"type":43},"2025-08-08",{"date":196,"type":23},"2025-09-01",{"date":198,"type":23},"2026-06-30",{"name":200,"class":149},"Hospital Israelita Albert Einstein",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":17,"sex":18,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":24,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":150},"100578787","phase-3-non-interference-study-of-mr-and-yellow-fever-vaccines-among-bangladeshi-infants-aged-9-12-months-100578787","NCT06815835","Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","A Prospective, Randomized, Parallel, Three-arm, Open-label, Clinical Trial to Evaluate the Immunological Non-interference of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) of M\u002Fs. Zydus Lifesciences Ltd. With Yellow Fever Vaccine Administered to Bangladeshi Healthy Infants Aged 9-12 Months","Inclusion Criteria:\n\n* The participant must satisfy all the following criteria to be eligible for enrolment:\n* Healthy infant participants of either gender aged\\* 9 to 12 months at the time of enrollment\n* Participants should be in good health as determined by the medical history and physical examination based on the clinical judgment of the investigator\n* No previous history of vaccination against measles, rubella, or Yellow fever\n* Written informed consent from the participant's parent\u002Fguardian\n* Participant's parent\u002Fguardian literate enough to fill the diary card \\*Age calculated as per completed month\n\nExclusion Criteria:\n\n* Participants positive for serological markers against Dengue and\u002For Japanese Encephalitis infections\n* History of hypersensitivity reaction to any component of the study vaccines including egg and chicken proteins\n* History of hypersensitivity reaction to neomycin\n* History of laboratory-confirmed or suspected measles, rubella, or Yellow fever in the past\n* Participant exposed# to measles, rubella, or Yellow fever virus within the past 30 days\n* Fever of any origin or infectious disorder of 3 days or more within the past month\n* Febrile illness (axillary temperature ≥37.5°C) at the time of enrollment\n* History of any vaccination within the past month\n* Clinically significant systemic disorders such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, immunological, or metabolic disorder\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or participants on any immunosuppressive or immunostimulant therapy\n* Known case of thrombocytopenia or any coagulation disorder, or participants on anticoagulation therapy\n* Participants administered blood, blood-containing products, or immunoglobulins within the last 3 months or planned administration during the study\n* Participant participated in another clinical study in the past 3 months\n* Any other reason for which the investigator feels that the participant should not participate #Close contact (family member or neighbour) with laboratory-confirmed or clinical diagnosis of measles\u002Frubella\u002FYellow fever","9 Months","12 Months",{"count":211,"type":23},1530,[26],"This study will be conducted among 1530 healthy infants of 9 to 12 months of age residing in the Dakshinkhan and Uttarkhan area which is located in Dhaka North City Corporation (DNCC) to enroll the required number of participants. Only infants who have not previously received the MR and YF vaccines will be enrolled. The findings of this study are likely to have a significant impact on vaccine co-administration strategies for campaign and routine immunization programs. The participants will be assigned to one of the three groups by the central computer-generated randomization schedule. The numbers are defined for each arm (Table 1) based on the sample size calculation. A list of infants who did not receive MR and Yellow fever vaccine will be prepared before enrollment by trained study staff (TSS). The TSSs will visit households in the defined study area and ask if the parents\u002Fguardians of infants aged 9-12 months are willing to participate in the study. If they show a willingness to participate, the TSSs will check their vaccination cards (if available) and prepare the list of potentially eligible infants who have not received MR and Yellow fever vaccines based on their vaccination card status. The investigators will collect blood specimens (4-5 ml) at the time of screening (visit-1), to evaluate serological markers of dengue and Japanese Encephalitis infection and for baseline (pre-vaccination) immunological assessment. The investigators will vaccinate seronegative, eligible participants within 24 hours of blood collection. There will be additional three follow-up visits after enrollment and will collect around 3-4 ml blood from each participant during visit 4 (week 6), and visit 5 (week 26) for immunological assessment. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data for vaccinated participants (up to 14 days for solicited and 6 weeks for unsolicited AEs). Medically attended adverse events (MAAEs) and data on serious adverse events (SAEs) will be reported during the study. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor.",[29,31,82],[216,217,218,219,36],"Safety","Non-interference","Measles and Rubella","Co-administration","2025-02-06",{"date":222,"type":43},"2025-02-07",{"date":224,"type":23},"2025-04-01",{"date":226,"type":23},"2026-03-31",{"name":228,"class":149},"International Centre for Diarrhoeal Disease Research, Bangladesh"]